Syndax Pharmaceuticals, Inc. Royalty Expense
Syndax Pharmaceuticals, Inc. (SNDX) reported Royalty Expense of $12.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. royalty expense for the quarter ending 2026-06-30 was $12.12M, a 54.30% increase year-over-year.
- Syndax Pharmaceuticals, Inc. royalty expense for the quarter ending 2026-03-31 was $11.85M, a 47.17% increase year-over-year.
- Syndax Pharmaceuticals, Inc. royalty expense for the quarter ending 2025-12-31 was $9.59M, a 94.58% increase year-over-year.
- Syndax Pharmaceuticals, Inc. royalty expense for the quarter ending 2025-09-30 was $8.28M.
- Syndax Pharmaceuticals, Inc. royalty expense for fiscal 2025 was $33.78M, a 585.17% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. royalty expense for fiscal 2024 was $4.93M.
- Syndax Pharmaceuticals, Inc. royalty expense for fiscal 2023 was $0.00.
| Period end | Royalty Expense 3 month | Royalty Expense 6 month | Royalty Expense 9 month | Royalty Expense 12 month | Royalty Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $12.12M 10-Q · filed 2026-08-04 | $23.96M 10-Q · filed 2026-08-04 | $33.56M derived: sum of 3 quarters · filed 2026-08-04 | $41.84M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $11.85M 10-Q · filed 2026-04-30 | $21.44M derived: sum of 2 quarters · filed 2026-04-30 | $29.72M derived: sum of 3 quarters · filed 2026-04-30 | $37.58M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $9.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.88M derived: sum of 2 quarters · filed 2026-02-26 | $25.73M derived: sum of 3 quarters · filed 2026-08-04 | $33.78M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $8.28M 10-Q · filed 2025-11-03 | $16.14M derived: sum of 2 quarters · filed 2026-08-04 | $24.19M 10-Q · filed 2025-11-03 | $29.12M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $7.85M 10-Q · filed 2026-08-04 | $15.90M 10-Q · filed 2026-08-04 | $20.83M derived: sum of 3 quarters · filed 2026-08-04 | $20.83M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $8.05M 10-Q · filed 2026-04-30 | $12.98M derived: sum of 2 quarters · filed 2026-04-30 | $12.98M derived: sum of 3 quarters · filed 2026-04-30 | $12.98M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $4.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.93M derived: sum of 2 quarters · filed 2026-02-26 | $4.93M derived: sum of 3 quarters · filed 2026-02-26 | $4.93M 10-K · filed 2026-02-26 | $300.00K 10-Q · filed 2025-11-03 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-04 | $0.00 10-Q · filed 2025-08-04 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | ||||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |